Susta-Med, Testosterone Mix, 300 mg/ml, 10 ml

Susta-Med 300 mg/ml by Bioniche Pharma is a high-potency multi-ester injectable testosterone matrix incorporating four complementary testosterone esters. Designed by Bioniche Pharma to achieve a sustained, phased-release pharmacokinetic profile, Bioniche Pharma Susta-Med supplies fast, intermediate, and long-acting testosterone to effectively address hypogonadal conditions, stimulate nitrogen balance, and encourage tissue regeneration.

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

The staggered release design of short (propionate), intermediate (phenylpropionate, isocaproate), and extended (decanoate) esters in Bioniche Pharma Susta-Med delivers a quick therapeutic onset followed by steady physiological hormone concentrations over several weeks. Following deep intramuscular injection, Susta-Med by Bioniche Pharma interacts directly with intracellular androgen receptors, promoting skeletal muscle protein translation, enhancing nitrogen conservation, accelerating red blood cell synthesis, and maintaining bone mineral density without extreme serum fluctuations.

INDICATIONS & CLINICAL USE

Recommended for androgen replacement therapy in adult men presenting with primary or secondary hypogonadal disorders resulting from endogenous testosterone deficiency:

• Primary hypogonadism secondary to orchidectomy, testicular torsion, or surgical castration.
• Eunuchoid states as well as congenital or acquired testicular failure managed with Bioniche Pharma Susta-Med.
• Hypopituitarism and hypothalamic-pituitary axis dysfunction.
• Secondary osteoporosis linked to chronic male hypogonadism and systemic androgen insufficiency.

CONTRAINDICATIONS

• Male patients with diagnosed or suspected carcinoma of the prostate gland or male breast cancer.
• Female patients, pregnant women, and breastfeeding mothers due to profound risks of fetal virilization and systemic endocrine disruption.
• Documented hypersensitivity or allergic response to any of the four testosterone esters, vehicle oils, or compounding ingredients in Bioniche Pharma Susta-Med.

WARNINGS & SPECIAL PRECAUTIONS

• Cardiovascular Supervision: Middle-aged and elderly male patients with underlying angina pectoris, ischemic heart disease, or circulatory dysfunction should receive Bioniche Pharma Susta-Med only under close clinical oversight.
• Fluid & Electrolyte Balance: Exogenous androgens promote renal retention of sodium, potassium, chloride, and water. Careful medical monitoring is warranted in individuals with a history of congestive heart failure, hypertension, renal impairment, epilepsy, or migraine disorders.
• Pediatric Caution: Extreme caution is required in prepubescent males to avoid precocious sexual development and early epiphyseal closure, which can permanently impair adult height.
• Laboratory Interference: Temporary reductions in protein-bound iodine (PBI) levels may be observed during Bioniche Pharma Susta-Med therapy without clinical thyroid impairment.

ADVERSE REACTIONS & CLINICAL REASSESSMENT

• Endocrine & Reproductive: Priapism, heightened libido, reduced sperm count (oligospermia), diminished ejaculatory volume, testicular suppression, and gynecomastia associated with Susta-Med by Bioniche Pharma.
• Prepubertal Effects: Acceleration of skeletal maturation, phallic enlargement, and increased erection frequency.
• Systemic & Dermatological: Fluid and sodium conservation presenting as peripheral edema, acne vulgaris, increased sebum production, and altered lipid profiles (elevated LDL, reduced HDL).
• Action Plan: Should severe androgen-related adverse events develop, treatment with Bioniche Pharma Susta-Med should be suspended temporarily. Upon resolution of symptoms, therapy may be cautiously re-initiated at a reduced dosage under medical supervision.

DOSAGE & ADMINISTRATION

Susta-Med by Bioniche Pharma is formulated exclusively for deep intramuscular injection. Dosing frequency and volume should be tailored based on individual clinical response and lab parameters:

• Therapeutic Schedule: Standard androgen replacement regimens generally involve a single 1 ml injection (300 mg total) of Bioniche Pharma Susta-Med administered every 3 to 4 weeks under medical direction.
• Restricted Populations: Strictly contraindicated for female patients, pediatric populations, and adolescents.

STORAGE & HANDLING

Store Bioniche Pharma Susta-Med in a dry, cool location protected from direct sunlight exposure and elevated heat. Do not refrigerate or freeze. Store safely out of the reach and sight of children.